NEUROONE MEDICAL TECHNOLOGIES CORP
NASDAQ: NMTC (NeuroOne Medical Technologies C)
Last update: 5 hours ago0.000
0.00 (0.00%)
| Price / Sales | 1.86 |
| Price / Book | 4.98 |
| Profit Margin | -114.67% |
| Operating Margin (TTM) | -193.29% |
| Diluted EPS (TTM) | -0.230 |
| Quarterly Revenue Growth (YOY) | 0.70% |
| Total Debt/Equity (MRQ) | 27.66% |
| Current Ratio (MRQ) | 2.13 |
| Operating Cash Flow (TTM) | -4.88 M |
| Levered Free Cash Flow (TTM) | -2.66 M |
| Return on Assets (TTM) | -83.48% |
| Return on Equity (TTM) | -265.18% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Mixed |
| Medical Devices (Global) | Mixed | Mixed | |
| Stock | NeuroOne Medical Technologies C | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | 3.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | 1.67 |
|
NeuroOne Medical Technologies Corp operates as a medical technology company. It is focused on the development and commercialization of thin-film electrode technology for continuous electroencephalogram (cEEG) and stereoelectrocencephalography (sEEG) recording, brain stimulation, and ablation solutions for patients suffering from brain-related disorders. The company business is in one operating segment, which is the business of development and commercialization of products related to comprehensive neuromodulation cEEG and sEEG recording, monitoring, ablation, and brain stimulation solutions. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Growth |
| % Held by Insiders | 11.56% |
| % Held by Institutions | 10.96% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Bleichroeder Lp | 30 Jun 2026 | 666,666 |
| Bard Associates Inc | 30 Jun 2026 | 305,428 |
| Perkins Capital Management Inc | 30 Jun 2026 | 244,656 |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |